Abstract

Purpose- To examine the effectiveness of Intravitreal
biosimilar Ranibizumab injection (Injection RanizuRel) in the
management of APROP
Methods- This is a retrospective pilot study conducted over 1
year in which 50 eyes with APROP were chosen from outdoor
and SNCU among 28 infants. Each of eye received 0.01
mg/0.1 ml of Injection RanizuRel aseptically in presence of
Paediatrician. They were examined weekly and followed up
upto the age of 6 months of age
Results- 14 out of 50 eyes(28%) showed regressing APROP
without having staging or plus disease and did not require
laser therapy. 32 eyes out of 50(64%) needed laser photo
coagulation in the avascular zone 2 and/or 3 after 50 weeks of
age. 4 eyes(8%) showed reactivation after 3-4 weeks of
injection and needed laser therapy in the avascular zone
Conclusion- Although most of the patients required laser
photocoagulation therapy but by the age of 6 months all the
babies showed satisfactory results by reducing risk of progression